Rome, Nov 13. (Adnkronos Health) – “This tumor doesn’t give much time, unfortunately, and we must fight to try to live a little longer.” With these words, Jessica Scarpa, 36, who has been suffering from metastatic pancreatic cancer for 2 years, addresses anyone who listens to her in a new video published on the Change.org Italia channels. Her invitation is just one: “Sign the petition that asks to make daraxonrasib accessible throughout Italy.” The petition, with over 42,000 signatures, was promoted by Emanuela, whose mother is ill, on Change.org’s social media.
“My name is Emanuela. My mother, a tireless fighter in her battle against pancreatic adenocarcinoma, is facing a critical moment. After six cycles of first-line chemotherapy, her therapy stopped working,” she writes in the petition. “Since then, we have been looking for an alternative. It exists and is called daraxonrasib: a drug that could slow down the progression of her tumor. For this reason – she continues – I ask the Minister of Health Orazio Schillaci to accelerate access to daraxonrasib for compassionate use for pancreatic cancer patients and to work towards making the drug available in Europe as well.” Hence Jessica Scarpa’s video appeal to help Emanuela, an appeal that exceeded 200,000 views in 24 hours. On November 5, the Lombardy Region announced that it will purchase the drug, already available in the United States, to allow Jessica to receive treatment at Lecco hospital, where she is being followed. A decision welcomed as wonderful news, which however highlighted a disparity: today, in Italy, access to this therapy depends on individual regional decisions, private fundraising, or the possibility of going abroad.
The voices of Jessica Scarpa and Emanuela are the latest to call for an acceleration of the definitive EU approval of daraxonrasib against metastatic pancreatic cancer. In recent months, pressure has grown for access to the drug of hope: after repeated appeals from the scientific community and the Third Sector (from Aiom oncologists to the Paola Marella Ets Foundation, created in memory of the TV presenter, architect, and designer, who died in 2024 from pancreatic cancer), and stories reported in the news (with radio speaker Max Parisi flying to the USA to get the treatment), the fundraising campaign to enable the therapy, launched by Scarpa herself, and the parliamentary question announced by the MEP of Fratelli d’Italia Lara Magoni. Objective: to ask the European Commission to “provide concrete answers to those facing one of the most aggressive oncological diseases and allow patients to access, as quickly as possible, the new opportunities offered by research.” Following the mid-October green light from the European Medicines Agency (EMA), with the positive opinion expressed by the Chmp technical committee on daraxonrasib in the treatment of metastatic pancreatic adenocarcinoma, the ball has now passed to the EU Commission, whose approval Magoni is urging.
“I am grateful to the Lombardy Region: this drug gives me hope of having more time with my children – explained Jessica Scarpa – But it cannot be an option only for me. There are many people in my same situation who have no time to lose: for this reason, I ask that daraxonrasib be approved in Italy as soon as possible, for everyone.” In the video, Jessica explains that hers is a battle for all patients: “The drug is essential for everyone. It’s not certain that it will work for everyone, but we all have the right to try. Each of us has children, grandchildren, a brother, a sister, parents: even just a few more days, for us, means a lot.”